Clinical trials: γδ T Cells
CAR, Malignant Tumors
CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors
This is a study on the clinical application of chimeric antigen receptor modified γδ T cells (CAR - γδ T cells) in relapsed and refractory CD7 Positive T cell-derived malignant tumors.The main purpose of this study was to…
- Trial name
- NCT04702841
- Testing
- Chimeric antigen receptor modified γδ T cells
- Where
- China
- Volunteers
- 8 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.